AbbVie to acquire TeneoOne and multiple myeloma drug from Teneobio
The deal is made possible via AbbVie’s exercise of its exclusive right to purchase TeneoOne and TNB-383B. The acquisition option was part of a strategic alliance formed with
Arrowhead Pharmaceuticals has signed a global collaboration and license agreement with Horizon Therapeutics for the development of RNA interference (RNAi) therapeutic, ARO-XDH. ARO-XDH is a discovery-stage investigational RNAi